as 05-30-2025 4:00pm EST
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | MALVERN |
Market Cap: | 36.4M | IPO Year: | 2019 |
Target Price: | $6.00 | AVG Volume (30 days): | 152.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.29 | EPS Growth: | N/A |
52 Week Low/High: | $0.86 - $6.00 | Next Earning Date: | 05-08-2025 |
Revenue: | $71,217,000 | Revenue Growth: | 12.78% |
Revenue Growth (this year): | 26.37% | Revenue Growth (next year): | 22.68% |
TELA Breaking Stock News: Dive into TELA Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
GlobeNewswire
22 days ago
GuruFocus.com
23 days ago
Zacks
23 days ago
GlobeNewswire
23 days ago
GuruFocus.com
24 days ago
Simply Wall St.
a month ago
GuruFocus.com
a month ago
The information presented on this page, "TELA TELA Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.